Niagen Bioscience, Inc. (FRA:OCD1)
Germany flag Germany · Delayed Price · Currency is EUR
5.70
+0.10 (1.79%)
At close: Nov 28, 2025

Niagen Bioscience Company Description

Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products.

The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services.

It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+) test kits to healthcare practitioners; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceuticalgrade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products.

The company also offers the supply of phytochemical reference standards and other research and development services.

In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name.

The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States.

The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025.

Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.

Niagen Bioscience, Inc.
CountryUnited States
Founded1999
IndustryMedicinal Chemicals and Botanical Products
Employees104
CEORobert Fried

Contact Details

Address:
10900 Wilshire Blvd
Los Angeles, Delaware 90024
United States
Phone310 388 6706
Websiteniagenbioscience.com

Stock Details

Ticker SymbolOCD1
ExchangeFrankfurt Stock Exchange
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
SIC Code2833

Key Executives

NamePosition
Robert FriedChief Executive Officer
Ozan PamirChief Financial Officer